Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes - Wikidata - awgldk - TriplyDB

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

http://www.wikidata.org/entity/Q26766180

about

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.Best Practices in Treatment Selection for Patients With Advanced NSCLC.

P2860

Q47100701-5F31A60F-6514-4C39-8126-68F98B4F2DE8 Q52814108-896F31AC-B792-4D5A-A7BC-1FEC3616F0EB

P2860

Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes

http://www.wikidata.org/entity/Q26766180

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@ast

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@en

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@nl

type

label

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@ast

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@en

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@nl

prefLabel

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@ast

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@en

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@nl

P1433

Q26766180-66C9FFC9-4C77-4060-ACB7-388F824D0622

P1476

Q26766180-9856AD96-BFF3-4A72-8AF2-307CDAD4E0EE

P2093

Q26766180-29175322-4D8A-4F8D-AC04-193044079E5A

Q26766180-5DD44FB5-5112-4CDA-887A-4C118551100A

P2860

Q26766180-0F23D9F0-45BB-419D-B47C-DE2A08BEA459

Q26766180-1912DDFB-8536-49CE-A568-A992B3212C2F

Q26766180-1E734C3E-3E47-4D9B-9707-4BE148830309

Q26766180-22E4CED2-D001-43AF-A478-4A986CBB4979

Q26766180-24C9FE18-72C9-4654-9405-0475A54B3AF1

Q26766180-2534DB99-4E98-4530-A109-C7BF443E8CB5

Q26766180-28912646-066E-462A-B0CB-3911B45A1EBF

Q26766180-2C0894A4-EE92-466E-AC42-D507922AB4BC

Q26766180-2C284FEF-81AC-4873-8103-254112601B23

Q26766180-2D863F3A-669F-4A1D-8CF6-78006D5111A8

P304

Q26766180-9C53B364-B520-4958-B1AD-3A5F3F173CA0

P31

Q26766180-B9D66114-A42E-4397-B15F-9EEFA1A25B11

P356

Q26766180-BEB5B19D-AB8C-4473-87D3-F10BBEF208AD

P407

Q26766180-91987C5C-9FD5-43FD-8ACC-B9DD9932C61F

P478

Q26766180-B5D76DC8-84EF-4399-863B-EBF9EB3B4A20

P577

Q26766180-13B9BFBB-BD8B-4B76-B62C-4995C52B34CD

P698

Q26766180-77A654E6-F7D3-4D1F-9FF2-3F227804E631

P932

Q26766180-53B8098A-BF32-4A98-BAA6-779979A326FC

P356

J.EJCA.2015.12.022

P1433

European Journal of Cancer

P1476

Is there a role of nab-paclita ...... g cancer? The data suggest yes

@en

P2093

Liza C Villaruz

http://www.w3.org/2001/XMLSchema#string

Mark A Socinski

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Cancer statistics, 2015

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer.

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

P304

162-71

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EJCA.2015.12.022

http://www.w3.org/2001/XMLSchema#string

P407

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26875112

http://www.w3.org/2001/XMLSchema#string

P932

4844000

http://www.w3.org/2001/XMLSchema#string